CERT — Certara, Inc.

Nasdaq · Information Technology · Software · CIK 1827090 ·
Last close
$6.77
Market Cap
$1.05B
52W High
$7.39
52W Low
$4.45
ADV30
4,688,197
Next earnings
2026-08-06
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 106,915,000 65,297,000 -4,303,000 -8,763,000 1,500,368,000 149,484,000 483,324,000
Dec 2025 103,648,000 64,477,000 836,000 -5,895,000 1,556,582,000 189,392,000 493,787,000
Sep 2025 104,616,000 64,898,000 3,005,000 1,525,000 1,535,856,000 172,711,000 471,049,000
Jun 2025 104,570,000 63,854,000 9,552,000 -1,968,000 1,543,446,000 162,266,000 472,867,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$90,667,000
Investing CF
$-27,563,000
Financing CF
$-93,731,000
CapEx
$-27,563,000
Dividends Paid
Buybacks
$-82,610,000
EPS Diluted TTM
$-0.10
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-138,639,000
Inventory
Receivables
$107,606,000
ST Investments
EBIT TTM
$15,004,000
Pretax Income TTM
$-4,869,000
Interest Exp TTM
$19,873,000
Analysts
11

Yahoo Snapshot (yfinance, live)

Total Revenue
$419,748,992
EBITDA
$94,029,000
Free Cash Flow
$116,569,376
Enterprise Value
$1,211,429,632
Total Cash
$149,510,000
Total Debt
$304,656,000
Shares Out
155,564,608
Trailing EPS
$-0.10
Book Value
$6.63
ROE
-1.4%
ROA
0.8%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 418,838,000 21,016,000 -1,595,000 1,556,582,000 493,787,000 96,325,000
Dec 2024 385,148,000 -1,731,000 -12,051,000 1,575,104,000 516,448,000 80,466,000
Dec 2023 354,337,000 6,210,000 -55,357,000 1,563,140,000 516,300,000 82,755,000
Dec 2022 335,644,000 32,521,000 14,731,000 1,572,922,000 493,261,000 92,543,000

TTM Snapshot

Revenues TTM
$265,096,000
NetIncome TTM
$-46,400,000
OpCashFlow TTM
$0
Assets (Latest)
$1,575,104,000
Forward EPS
$0.41

Max Pain — expiry 2026-08-21 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $6.77 · call volume: 2,401 · put volume: 2
Expected Move to 2026-08-21: ±$1.60 (23.63%) — implied range $5.17$8.37 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
BLZE Backblaze, Inc. $1.06B $17.60
APPN APPIAN CORP $1.07B $25.36
TUYA Tuya Inc. $999.02M $1.84
VERX Vertex, Inc. $986.21M $12.38
RDVT Red Violet, Inc. $953.62M $67.59

News headlines (Yahoo Finance, 1h cache)

Bank of America Securities Reiterates Buy Rating on Nvidia (NVDA)
2026-07-10 06:58 · Yahoo
NVIDIA (NVDA): The Best NASDAQ 100 Stock to Buy Other Than SpaceX
2026-07-09 16:44 · Yahoo
AI Chips Today - Certara-NVIDIA Partnership Revolutionizes AI in Drug Development
2026-07-08 11:37 · Yahoo
Certara teams up with Nvidia to strengthen AI platform with BioNeMo toolkit (CERT)
2026-07-07 12:54 · Yahoo
Certara Accelerates Drug Discovery and Development with NVIDIA BioNeMo Agent Toolkit
2026-07-07 12:00 · Yahoo
Is Certara (CERT) Quietly Recasting Its Small-Cap Identity Around Biosimulation Advisory Leadership?
2026-07-02 17:08 · Yahoo
[Latest] Global In Silico Clinical Trials Market Size/Share Worth USD 8.94 Billion by 2035 at a 15.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, G
2026-06-26 06:30 · Yahoo
Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development
2026-06-23 11:05 · Yahoo
Will CONMED’s New CFO Shift CNMD’s Financial Playbook Or Deepen Its Existing Strategy?
2026-06-21 11:09 · Yahoo
Certara (CERT) Stock Sees Fair Value Edges Lower As Analysts Trim Targets
2026-06-20 01:09 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.